Ovr110 antibody compositions and methods of use
AssigneediaDexus, Inc.
InventorsGlenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
Life of this patent
Estimating the term…
Loading patent…
AssigneediaDexus, Inc.
InventorsGlenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
Estimating the term…
The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
An isolated Ovr110 antibody that binds to Ovr110 on a mammalian cell in vivo.
3-4. (canceled)
(canceled)
(canceled)
13-15. (canceled)
An anti-Ovr110 monoclonal antibody that inhibits the growth of Ovr110-expressing cancer cells in vivo.
(canceled)
(canceled)
23-24. (canceled)
(canceled)
(canceled)
32-36. (canceled)
39-46. (canceled)
49-50. (canceled)
52-60. (canceled)
64-71. (canceled)
Dependencies are inferred from the claim text.